The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

Here are five GI groups leveraging new techniques, technologies and developments to make the most of increased demand for GI services.

AstraZeneca’s AZD0901 is in Phase 3 testing in advanced gastric and GEJ cancers. Elevation Oncology’s ADC, EO-3021, is in early clinical development for advanced solid tumors, including GI ...